| dbo:abstract |
L'ubrogepant est une molécule inhibitrice du récepteur au peptide relié au gène calcitonine, utilisé comme médicament de la migraine. (fr) Ubrogepant, sold under the brand name Ubrelvy, is a medication used for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. It is not indicated for the preventive treatment of migraine. Ubrogepant is a small-molecule calcitonin gene-related peptide receptor antagonist. It is the first drug in this class approved for the acute treatment of migraine. The most common side effects are nausea, tiredness and dry mouth. Ubrogepant is contraindicated for co-administration with strong CYP3A4 inhibitors. (en) Уброгепант — лекарственный препарат для лечения мигрени. Одобрен для применения: США(2019). (ru) |
| dbo:alternativeName |
Ubrelvy (en) |
| dbo:casNumber |
1374248-77-7 |
| dbo:chEMBL |
2364638 |
| dbo:drugbank |
DB15328 |
| dbo:fdaUniiCode |
AD0O8X2QJR |
| dbo:kegg |
D10673 |
| dbo:medlinePlus |
a620016 |
| dbo:pubchem |
68748835 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Ubrogepant.svg?width=300 |
| dbo:wikiPageExternalLink |
https://druginfo.nlm.nih.gov/drugportal/name/ubrogepant http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ubrelvy |
| dbo:wikiPageID |
57672434 (xsd:integer) |
| dbo:wikiPageLength |
9006 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1120145439 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:United_States_National_Library_of_Medicine dbc:Spiro_compounds dbc:Trifluoromethyl_compounds dbr:Nausea dbr:Calcitonin_gene-related_peptide_receptor_antagonist dbc:Piperidinones dbr:Fatigue dbr:Allergan dbc:Carboxamides dbr:Food_and_Drug_Administration dbc:Antimigraine_drugs dbc:Pyridines dbc:Calcitonin_gene-related_peptide_receptor_antagonists dbc:AbbVie_brands dbr:Migraine dbr:Medication dbr:Xerostomia |
| dbp:atcPrefix |
N02 (en) |
| dbp:atcSuffix |
CD04 (en) |
| dbp:c |
29 (xsd:integer) |
| dbp:casNumber |
1374248 (xsd:integer) |
| dbp:chembl |
2364638 (xsd:integer) |
| dbp:chemspiderid |
28536135 (xsd:integer) |
| dbp:dailymedid |
Ubrogepant (en) |
| dbp:drugbank |
DB15328 (en) |
| dbp:f |
3 (xsd:integer) |
| dbp:h |
26 (xsd:integer) |
| dbp:iupacName |
120.0 |
| dbp:kegg |
D10673 (en) |
| dbp:legalUs |
Rx-only (en) |
| dbp:medlineplus |
a620016 (en) |
| dbp:n |
5 (xsd:integer) |
| dbp:o |
3 (xsd:integer) |
| dbp:pubchem |
68748835 (xsd:integer) |
| dbp:pubchemsubstance |
254741634 (xsd:integer) |
| dbp:smiles |
C[C@@H]1[C@H]C[C@H]CN1CCF (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
DDOOFTLHJSMHLN-ZQHRPCGSSA-N (en) |
| dbp:synonyms |
MK-1602 (en) |
| dbp:tradename |
Ubrelvy (en) |
| dbp:unii |
AD0O8X2QJR (en) |
| dbp:wikiPageUsesTemplate |
dbt:Analgesic-stub dbt:Cite_web dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Short_description dbt:Use_dmy_dates dbt:Triptans dbt:Drugs.com |
| dcterms:subject |
dbc:Spiro_compounds dbc:Trifluoromethyl_compounds dbc:Piperidinones dbc:Carboxamides dbc:Antimigraine_drugs dbc:Pyridines dbc:Calcitonin_gene-related_peptide_receptor_antagonists dbc:AbbVie_brands |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment |
L'ubrogepant est une molécule inhibitrice du récepteur au peptide relié au gène calcitonine, utilisé comme médicament de la migraine. (fr) Ubrogepant, sold under the brand name Ubrelvy, is a medication used for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. It is not indicated for the preventive treatment of migraine. Ubrogepant is a small-molecule calcitonin gene-related peptide receptor antagonist. It is the first drug in this class approved for the acute treatment of migraine. The most common side effects are nausea, tiredness and dry mouth. Ubrogepant is contraindicated for co-administration with strong CYP3A4 inhibitors. (en) Уброгепант — лекарственный препарат для лечения мигрени. Одобрен для применения: США(2019). (ru) |
| rdfs:label |
Ubrogepant (fr) Уброгепант (ru) Ubrogepant (en) |
| owl:sameAs |
wikidata:Ubrogepant dbpedia-fr:Ubrogepant dbpedia-ru:Ubrogepant https://global.dbpedia.org/id/2YPxf |
| prov:wasDerivedFrom |
wikipedia-en:Ubrogepant?oldid=1120145439&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Ubrogepant.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Ubrogepant |
| is dbo:wikiPageRedirects of |
dbr:Ubrelvy |
| is dbo:wikiPageWikiLink of |
dbr:Calcitonin_gene-related_peptide dbr:Calcitonin_gene-related_peptide_receptor_antagonist dbr:Allergan dbr:ATC_code_N02 dbr:List_of_signaling_peptide/protein_receptor_modulators dbr:Management_of_chronic_headaches dbr:Migraine_treatment dbr:Signaling_peptide_receptor dbr:Ubrelvy |
| is foaf:primaryTopic of |
wikipedia-en:Ubrogepant |
